As has been said by the Carl June who did the pioneering work at UPen, this is like a targeted, safer version of a bone marrow transplant. The problem is gener

As has been said by the Carl June who did the pioneering work at UPen, this is like a targeted, safer version of a bone marrow transplant. The problem is generalising this to every type of cancer. You need a target that is widely expressed on the cancer cell, and that isn't found on other important tissues. This is the case (sort of - it still destroys all the healthy B-cells, which as it turns out, doesn't cause TOO many problems) for CD19 which the T-cells are aimed at in this study. For solid tumours like lung cancer, breast cancer, colon cancer etc it will probably be much harder to find a similarly useful target. But they are trying: http://cancerimmunolres.aacrjournals.org/content/early/2013/12/19/2326-6066.CIR-13-0170.abstract http://cancerimmunolres.aacrjournals.org/content/early/2013/...